Zofenopril

Zofenopril

Zofenopril

Antihypertensive drug of the ACE inhibitor class

Zofenopril (INN) is a medication that protects the heart and helps reduce high blood pressure. It is an angiotensin-converting enzyme (ACE) inhibitor.[1]

Quick Facts Clinical data, Trade names ...

In small studies, zofenopril appeared significantly more effective in reducing hypertension than two older antihypertensive drugs, atenolol and enalapril, and was associated with fewer adverse effects.[2][3]

Zofenopril is a prodrug with zofenoprilat as the active metabolite.[4]

It was patented in 1978 and approved for medical use in 2000.[5]

References

  1. [1]
    Ambrosioni E (2007). "Defining the role of zofenopril in the management of hypertension and ischemic heart disorders". American Journal of Cardiovascular Drugs. 7 (1): 17–24. doi:10.2165/00129784-200707010-00002. PMID 17355163. S2CID 41320204.
  2. [2]
    Nilsson P (October 2007). "Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension". Blood Pressure. Supplement. 2: 25–30. doi:10.1080/08038020701561745. PMID 18046976. S2CID 22145457.
  3. [3]
    Mallion JM (October 2007). "An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension". Blood Pressure. Supplement. 2: 13–18. doi:10.1080/08038020701561703. PMID 18046974. S2CID 27469549.
  4. [4]
    Subissi A, Evangelista S, Giachetti A (1999). "Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties". Cardiovascular Drug Reviews. 17 (2): 115–133. doi:10.1111/j.1527-3466.1999.tb00008.x.
  5. [5]
    Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3-527-60749-5.
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Zofenopril, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.